TY  - JOUR
T1  - Coupling of Some Carbazole Analogs with 3pjc Protein Surface as JAK3 Inhibitors
A1  - Lauro Figueroa-Valverde
A1  - Marcela Rosas-Nexticapa
A1  - Catalina Cervantes-Ortega
A1  - Magdalena Alvarez-Ramirez
A1  - Maria Lopez-Ramos
A1  - Emilio Aguilar-Sánchez
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2024
VL  - 13
IS  - 4
DO  - 10.51847/W6CrjgGwSK
SP  - 7
EP  - 14
N2  - Some studies indicate that Janus kinase 3 (JAK3) has been involved in several types of cancer. To treat this clinical pathology, some JAK3 inhibitors have been used, such as decernotinib, and facitinib; however, some of these drugs can produce increases in liver transaminase and lipid levels. It is noteworthy that novel medications have been created to inhibit the growth of cancer cells through various experimental and theoretical approaches. Accordingly, the purpose of this study was to ascertain whether carbazole analogs (1-25) could theoretically couple with JAK3, utilizing 3pjc protein, decernotinib, and facitinib as controls within DockingServer software. Data indicate that carbazole analogs could interact at different sites of 3pxb protein surface compared to decernotinib, and facitinib. Other results suggest that inhibition constant (Ki) related to carbazole-protein complexes formation for compounds 2, 5, 9, 17, 18, and 22 was lower compared to decernotinib and facitinib drugs. This phenomenon suggests that carbazole analogs 2, 5, 9, 17, 18, and 22 could act as JAK3 blockers agents resulting in a possible decrease of cancer cell growth.
UR  - https://ccij-online.org/article/coupling-of-some-carbazole-analogs-with-3pjc-protein-surface-as-jak3-inhibitors-falm99g9fq4ljar
ER  -